NY 338
Alternative Names: CYT-338; NY-338Latest Information Update: 14 Dec 2023
At a glance
- Originator Cytovia Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural cytotoxicity triggering receptor 1 agonists; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 11 Dec 2023 NAYA Biosciences plans a phase I trial in Multiple myeloma (Second-line therapy or greater) in the US in 2024
- 10 Dec 2022 Updated Pharmacodynamics data from the preclinical trials in Multiple myeloma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 09 Dec 2022 Preclincial pharmacodynamics and pharmacokinetics data in Multiple myeloma released by Cytovia Therapeutics